BioSpace News Archive

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following investor conferences and medical meetings: American Academy of Otolaryngology – Head & Neck Surgery (AAO-HNS) 2020 Virtual Annua

Savara Announces New England Journal of Medicine ( NEJM ) Publication of IMPALA Study Results Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramost

Xeris Pharmaceuticals to Present at the H.C. Wainwright 22 nd Annual Global Investment Conference

CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer,

Health Union has been accepted to present research, in the form of two poster presentations, around progressive forms of multiple sclerosis (MS) and disease-modifying therapies (DMT) at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

LIPAC Oncology LLC today announced the successful completion of a Phase 2A marker lesion clinical trial designed to predict long-term (two-year) recurrence free survival rates in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC) treated with LiPax (paclitaxel).

A 12-year-long collaboration with Canon Medical Research USA, Canon Medical Systems Japan and Southern Nevada outpatient radiology leader Steinberg Diagnostic Medical Imaging (SDMI) has resulted in the development of 3 PET Scanners, each generation more advanced than the last.

The Institute of Cancer Research, London, has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head and neck cancer.

More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates